WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...
WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...
SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...
Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...
Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...
US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to a Reuters report.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
WASHINGTON, Jan 24 (Reuters) - Chinese Foreign Minister Wang Yi spoke with new U.S. Secretary of State Marco Rubio on Friday and Beijing said he told the known China hawk that the direction and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback